Analysis of the actual efficacy and patient feedback of Epclusa in the treatment of hepatitis C

Epclusa (Epclusa) is a fully oral, pan-genotypic hepatitis C (HCV) antiviral drug composed of Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). As the world's first direct-acting antiviral drug (DAA) that covers all hepatitis C genotypes, G3 has been widely used in clinical practice since its launch. Its core advantages are high cure rate, short course of treatment and relatively mild side effects. The standard treatment course is 12 weeks, and most patients can achieve ideal results without interferon or ribavirin.

Clinical studies have shown that the sustained virological response rate (SVR12) of Jisandai in patients with different genotypes of hepatitis C generally exceeds 95%, which means that the vast majority of patients turn negative in virus tests after completing the course of treatment and maintain long-term recurrence-free. For patients with liver cirrhosis or previous treatment failure, Jisandai also shows good efficacy. For some special groups, such as patients with HIV infection, the efficacy data also show a cure rate similar to that of ordinary patients, further highlighting its broad spectrum and stability.

Judging from real feedback from patients, most people can successfully complete the course of treatment after using Jisandai. Common side effects include mild fatigue, headache and digestive discomfort, but most of them are within a tolerable range and will not significantly affect daily life. Some patients reported that their physical strength decreased in the early stages of treatment, but gradually improved as the course of treatment progressed. Compared with traditional interferon treatment, Gisanda not only significantly reduces side effects, but also avoids the pain of frequent injections, improving patient compliance and quality of life.

In general, Epclusa/Epclusa has become the current first-line standard treatment for hepatitis C, with both high efficacy and safety. Real-world feedback is basically consistent with clinical trial results, and patients are generally satisfied with the efficacy. For hepatitis C patients, persisting in completing the full course of treatment is the key to ensuring cure. At the same time, regular review and maintaining a good lifestyle, such as abstaining from alcohol, regular work and rest, and eating a reasonable diet, can further help the recovery of liver function and reduce the risk of disease recurrence.

Reference materials:https://www.drugs.com/